8-KEarnings & ResultsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Aug 6, 2015)

Filed August 6, 2015For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on August 6, 2015, primarily to announce its financial results for the quarter ended June 30, 2015. This filing serves as a notification to investors regarding the company's operational and financial performance during the specified period. The details of these results are contained within a press release furnished as an exhibit to this report, which investors should review for a comprehensive understanding of the company's financial standing. While the 8-K itself is a procedural filing, it signals that Alnylam has disclosed key financial metrics, such as revenue, expenses, and earnings, for the second quarter of 2015. Investors typically look to these announcements to assess the company's progress in its drug development pipeline, its cash burn rate, and its overall financial health as it advances its therapeutic candidates. The furnished press release is the primary source for this critical information.

Key Highlights

  • 1Alnylam Pharmaceuticals, Inc. reported its financial results for the quarter ended June 30, 2015.
  • 2The financial results were announced on August 6, 2015, via a press release.
  • 3The press release is furnished as Exhibit 99.1 to this Form 8-K filing.
  • 4This filing is an 8-K, indicating a significant event or announcement.
  • 5The company is incorporated in Delaware and headquartered in Cambridge, MA.
  • 6The filing provides information on financial condition and results of operations.
  • 7The information furnished is not deemed 'filed' for certain SEC liability purposes unless specifically incorporated by reference.

Frequently Asked Questions

The main purpose of this 8-K filing is to announce Alnylam Pharmaceuticals, Inc.'s financial results for the quarter ended June 30, 2015. The detailed financial information is provided in a press release furnished with the filing.

The specific financial details are contained within the press release dated August 6, 2015, which is included as Exhibit 99.1 to this Form 8-K filing.

The information in this Form 8-K, including the furnished press release, is generally not considered 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, unless the company specifically incorporates it by reference into another filing.

The press release would typically include key financial metrics such as revenue, cost of goods sold, operating expenses, net income or loss, and earnings per share for the quarter. It might also provide updates on the company's clinical pipeline, strategic partnerships, and business developments.